Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ:OLMA
Want to see OLMA full AI Analyst Report?
OLMA Stock Chart & Stats
$16.82
$0.55(10.50%)
At close: 4:00 PM EST
$16.82
$0.55(10.50%)
Day’s Range― - ―
52-Week Range$3.89 - $36.26
Previous CloseN/A
Volume1.27M
Average Volume (3M)1.04M
Market Cap
$933.74M
Enterprise Value$1.10B
Total Cash (Recent Filing)$505.35M
Total Debt (Recent Filing)$956.00K
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 11, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding87,347,470
10 Day Avg. Volume1,162,888
30 Day Avg. Volume1,038,003
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.60K
Enterprise Value/Ebitda-5.57
Forecast
1Y Price Target
$40.22Price Target Upside139.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.2
Revenue Forecast (FY)$2.05M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low leverage and meaningful equity growth give Olema durable financial flexibility to fund clinical programs and partnerships without immediate refinancing pressure. This reduces near-term solvency risk and supports strategic optionality (trials, combos, business development) as programs mature.
Strategic Bayer CollaborationThe Bayer collaboration expands Olema’s development footprint into prostate cancer, shares drug combination resources, and jointly owns combination data while Olema retains global commercial rights to OP-3136. Structurally this validates the program, lowers single-party execution risk, and broadens future commercialization pathways.
Encouraging OP-3136 Early Clinical Signals And Late-stage PalazestrantDemonstrated tolerability, target engagement, and tumor responses in early OP-3136 data raise the program’s probability of success and support combination strategies. Concurrent Phase 3 palazestrant programs provide a clear commercialization pathway, creating multi-program optionality and long-term franchise potential in endocrine-driven cancers.
Bears Say
Pre-revenue Status With Widening LossesOlema remains pre-revenue and loss-making, with materially widening net losses. Without product revenue, the company depends on external capital to sustain operations. Persistently negative profitability limits internal funding capacity and elevates the risk that development timelines will be interrupted if financing conditions tighten.
High And Worsening Cash BurnLarge, increasing negative operating and free cash flows signal a high and volatile burn rate. This durable cash consumption profile creates ongoing funding needs, raises dilution risk from future financing, and could force prioritization or delay of programs if additional capital is constrained.
Clinical Program Outcome Concentration RiskBusiness fundamentals hinge on successful clinical results from a small number of programs. Failure or delay in palazestrant or OP-3136 would materially impair the path to revenue and partnerships. This program concentration sustains binary outcome risk that can affect long-term viability absent diversification.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals, Inc.’s price range in the past 12 months?
Olema Pharmaceuticals, Inc. lowest stock price was $3.89 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals, Inc.’s market cap?
Olema Pharmaceuticals, Inc.’s market cap is $933.74M.
When is Olema Pharmaceuticals, Inc.’s upcoming earnings report date?
Olema Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 68 days.
How were Olema Pharmaceuticals, Inc.’s earnings last quarter?
Olema Pharmaceuticals, Inc. released its earnings results on May 12, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.531 by $0.011.
Is Olema Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Olema Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Olema Pharmaceuticals, Inc. pay dividends?
Olema Pharmaceuticals, Inc. does not currently pay dividends.
What is Olema Pharmaceuticals, Inc.’s EPS estimate?
Olema Pharmaceuticals, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Olema Pharmaceuticals, Inc. have?
Olema Pharmaceuticals, Inc. has 87,347,470 shares outstanding.
What happened to Olema Pharmaceuticals, Inc.’s price movement after its last earnings report?
Olema Pharmaceuticals, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.531. Following the earnings report the stock price went down -5.989%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in OLMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olema Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.22 (139.13% Upside)
$40.22 (139.13% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $951.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
144.34%
12-Months-Change
Fundamentals
Return on Equity
-45.95%
Trailing 12-Months
Asset Growth
29.54%
Trailing 12-Months
Company Description
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
OLMA Stock 12 Month Forecast
Average Price Target
$40.22
▲(139.13% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
10.22% Insiders
20.60% Mutual Funds
12.52% Other Institutional Investors
43.46% Public Companies and Individual Investors